Bill Lundberg takes over the reins at Merus; Former Akcea COO Jeffrey Goldberg takes the helm of Immunitas
→ Dutch biotech Merus, who struck up a $200 million bispecific development deal with Incyte …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
